Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06856278

Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC

The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Anaplastic Throid Carcinoma

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, 310014, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-75 years (including boundary values), male or female.
  • Be diagnosed with anaplastic thyroid cancer histopathologically with a measurable lesion≥1cm.
  • Liver and kidney function is good, and can tolerate treatment.
  • Be able to cooperate with the completion of treatment and follow-up work.
  • No other systemic diseases, including other malignancies.

Exclusion criteria

  • Need to breastfeed the baby or have fertility needs；
  • Immune system diseases;
  • Diseases of the blood system;
  • Mental system diseases;
  • Interstitial pneumonia, lung disease, etc.;
  • Failure to follow rules of this study.

Treatment and study plan

NKG2D CAR-NK with PD-1 Antibody

Drug

Treated with CAR-NK immune cells combined with PD-1 monoclonal antibody.

Primary outcomes

  1. Safety and tolerability

    Time frame: From the start of the trial to day 56 after the first infusion of CAR-NK.

    Safety and tolerability at 28 days after combination therapy, dose limiting toxicity (DLT) and maximum tolerated dose (MTD) were determined.

Study contacts

Contact information is provided by the study sponsor or research team.

Minghua Ge

CONTACT

[email protected]

+86-0571 87666666

Sponsors and collaborators

Lead sponsor

Zhejiang Provincial People's Hospital

Other

Registry information

Official study title

Clinical Exploratory Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of Anaplastic Thyroid Cancer (ATC)

Important dates

Study start
2025
Primary completion
2028
Study completion
2029
First posted
Mar 4, 2025
Registry last updated
Mar 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.